These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 20434528)

  • 21. Qualitative and quantitative differences in senile plaque dystrophic neurites of Alzheimer's disease and normal aged brain.
    Wang D; Munoz DG
    J Neuropathol Exp Neurol; 1995 Jul; 54(4):548-56. PubMed ID: 7602328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced accumulation of tau in doubly transgenic mice expressing mutant betaAPP and presenilin-1.
    Samura E; Shoji M; Kawarabayashi T; Sasaki A; Matsubara E; Murakami T; Wuhua X; Tamura S; Ikeda M; Ishiguro K; Saido TC; Westaway D; St George Hyslop P; Harigaya Y; Abe K
    Brain Res; 2006 Jun; 1094(1):192-9. PubMed ID: 16713590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in Mice.
    Ghosal K; Fan Q; Dawson HN; Pimplikar SW
    PLoS One; 2016; 11(7):e0159435. PubMed ID: 27459671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.
    Chen Y; Zhao S; Fan Z; Li Z; Zhu Y; Shen T; Li K; Yan Y; Tian J; Liu Z; Zhang B
    Alzheimers Res Ther; 2021 Feb; 13(1):40. PubMed ID: 33563332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
    Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
    EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model.
    Meilandt WJ; Ngu H; Gogineni A; Lalehzadeh G; Lee SH; Srinivasan K; Imperio J; Wu T; Weber M; Kruse AJ; Stark KL; Chan P; Kwong M; Modrusan Z; Friedman BA; Elstrott J; Foreman O; Easton A; Sheng M; Hansen DV
    J Neurosci; 2020 Feb; 40(9):1956-1974. PubMed ID: 31980586
    [No Abstract]   [Full Text] [Related]  

  • 28. Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice.
    Héraud C; Goufak D; Ando K; Leroy K; Suain V; Yilmaz Z; De Decker R; Authelet M; Laporte V; Octave JN; Brion JP
    Neurobiol Dis; 2014 Feb; 62():100-12. PubMed ID: 24076100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.
    Maier M; Peng Y; Jiang L; Seabrook TJ; Carroll MC; Lemere CA
    J Neurosci; 2008 Jun; 28(25):6333-41. PubMed ID: 18562603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.
    Kurt MA; Davies DC; Kidd M; Duff K; Howlett DR
    Neurobiol Dis; 2003 Oct; 14(1):89-97. PubMed ID: 13678670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models.
    Bignante EA; Ponce NE; Heredia F; Musso J; Krawczyk MC; Millán J; Pigino GF; Inestrosa NC; Boccia MM; Lorenzo A
    Neurobiol Aging; 2018 Apr; 64():44-57. PubMed ID: 29331876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.
    Paulson JB; Ramsden M; Forster C; Sherman MA; McGowan E; Ashe KH
    Am J Pathol; 2008 Sep; 173(3):762-72. PubMed ID: 18669616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
    Lewis J; Dickson DW; Lin WL; Chisholm L; Corral A; Jones G; Yen SH; Sahara N; Skipper L; Yager D; Eckman C; Hardy J; Hutton M; McGowan E
    Science; 2001 Aug; 293(5534):1487-91. PubMed ID: 11520987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
    Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
    Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transgenic mouse models of Alzheimer's disease.
    Bornemann KD; Staufenbiel M
    Ann N Y Acad Sci; 2000 Jun; 908():260-6. PubMed ID: 10911965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis.
    Stein TD; Anders NJ; DeCarli C; Chan SL; Mattson MP; Johnson JA
    J Neurosci; 2004 Sep; 24(35):7707-17. PubMed ID: 15342738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport.
    Adalbert R; Milde S; Durrant C; Ando K; Stygelbout V; Yilmaz Z; Gould S; Brion JP; Coleman MP
    Neurobiol Aging; 2018 Aug; 68():68-75. PubMed ID: 29729423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.